<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01878643</url>
  </required_header>
  <id_info>
    <org_study_id>20033799</org_study_id>
    <nct_id>NCT01878643</nct_id>
  </id_info>
  <brief_title>Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit</brief_title>
  <official_title>Pilot Study of the Effects of Inhaled Antibiotic on Bacterial Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was :

        -  to determine the effect of inhaled antibiotics on airway bacteria in ventilated patients

        -  to determine the effect of inhaled antibiotics on respiratory infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind randomized placebo controlled study examining the effect of aerosolized
      antibiotics on respiratory infection signs and symptoms and on bacterial eradication and
      resistance.

      Systemic antibiotics are administered by the responsible physician
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication of multi-drug resistant bacteria</measure>
    <time_frame>Randomization and at end of treatment</time_frame>
    <description>Tracheal aspirates are taken at randomization. Randomization to drug is determined by the Gram stain(organisms are Gram-positive, Gram-negative or both). End of treatment culture, susceptibility and Gram stain of tracheal aspirate is taken after 14 days of treatment or at time of extubation, (which ever comes first).
Eradication is defined as absence of growth in culture and absence of organisms on Gram stain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Pulmonary Infection Score (CPIS)</measure>
    <time_frame>Randomization and at end of treatment which is defined as 14 days or at time of extubation, which ever comes first.</time_frame>
    <description>CPIS is an index for risk of respiratory infection using a number of signs and symptoms . An index of greater than or equal to 6 suggests pneumonia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Respiratory Infection</condition>
  <condition>Bacterial Resistance</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Drug: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline 2 mL nebulized Q 8 hours placebo for gentamicin or vancomycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: vancomycin or gentamicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vancomycin 120 mg every 8 hours or gentamicin 80 mg every 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vancomycin or gentamicin</intervention_name>
    <description>Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours</description>
    <arm_group_label>Drug: vancomycin or gentamicin</arm_group_label>
    <other_name>gentamicin sulfate</other_name>
    <other_name>vancomycin hydrocloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>normal saline administered to patient via nebulization</description>
    <arm_group_label>Drug: Placebo</arm_group_label>
    <other_name>Normal saline 2mL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be on mechanical ventilation greater than 3 days

          -  greater than or equal to 18 years and survival greater than 14 days

          -  organisms on Gram stain with increasing purulent secretions

        Exclusion Criteria:

          -  pregnancy

          -  allergy to drugs administered
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucy B Palmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Medical Center</name>
      <address>
        <city>STony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2013</study_first_posted>
  <last_update_submitted>June 12, 2013</last_update_submitted>
  <last_update_submitted_qc>June 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aerosolized antibiotic</keyword>
  <keyword>ventilator-associated pneumonia</keyword>
  <keyword>bacterial resistance</keyword>
  <keyword>ventilator -associated tracheobronchitis</keyword>
  <keyword>clinical pulmonary infection score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

